I agree. I listened to the call on October 19, 2017. Basically the FDA stated that for the efficacy to be relevant the company has to enroll 50. This was stated after the FDA saw the data for the 30 patients. The FDA decided that the data wouldn't be relevant with only the 30 patients so they upped the target to 50. You can't control how the FDA will react when it gets a response from a company. I understand people are frustrated because of the delay, but such a delay was not CYDY's fault. It was the FDA that changed their minds, and the FDA has every right to do whatever it wants.